TY - JOUR
T1 - Antinociceptive effect of (-)-epicatechin in inflammatory and neuropathic pain in rats
AU - Quinõnez-Bastidas, Geovanna N.
AU - Pineda-Farias, Jorge B.
AU - Flores-Murrieta, Francisco J.
AU - Rodriguez-Silverio, Juan
AU - Reyes-Garcia, Juan G.
AU - Godínez-Chaparro, Beatriz
AU - Granados-Soto, Vinicio
AU - Rocha-Gonzalez, Héctor I.
N1 - Publisher Copyright:
© 2018 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2018/6/5
Y1 - 2018/6/5
N2 - The aim of this study was to investigate the antinociceptive potential of (.)-epicatechin and the possible mechanisms of action involved in its antinociceptive effect. The carrageenan and formalin tests were used as inflammatory pain models. A plethysmometer was used to measure inflammation and L5/L6 spinal nerve ligation as a neuropathic pain model. Oral (-)-epicatechin reduced carrageenan-induced inflammation and nociception by about 59 and 73%, respectively, and reduced formalininduced and nerve injury-induced nociception by about 86 and 43%, respectively. (-)-Epicatechin-induced antinociception in the formalin test was prevented by the intraperitoneal administration of antagonists: Methiothepin (5-HT 1/5 receptor), WAY-100635 (5-HT 1A receptor), SB-224289 (5-HT 1B receptor), BRL-15572 (5-HT 1D receptor), SB-699551 (5-HT 5A receptor), naloxone (opioid receptor), CTAP (κopioid receptor), nor-binaltorphimine (δ 1 opioid receptor), and 7-benzylidenenaltrexone (δ 1 opioid receptor). The effect of (-)-epicatechin was also prevented by the intraperitoneal administration of L-NAME [nitric oxide (NO) synthase inhibitor], 7-nitroindazole (neuronal NO synthase inhibitor), ODQ (guanylyl cyclase inhibitor), glibenclamide (ATP-sensitive K + channel blocker), 4-aminopyridine (voltage-dependent K + channel blocker), and iberiotoxin (large-conductance Ca 2+ -activated K+ channel blocker), but not by amiloride (acid sensing ion channel blocker). The data suggest that (-)-epicatechin exerts its antinociceptive effects by activation of the NO-cyclic GMP-K+ channels pathway, 5-HT 1A/1B/1D/5A serotonergic receptors, and μ/κ/δ opioid receptors.
AB - The aim of this study was to investigate the antinociceptive potential of (.)-epicatechin and the possible mechanisms of action involved in its antinociceptive effect. The carrageenan and formalin tests were used as inflammatory pain models. A plethysmometer was used to measure inflammation and L5/L6 spinal nerve ligation as a neuropathic pain model. Oral (-)-epicatechin reduced carrageenan-induced inflammation and nociception by about 59 and 73%, respectively, and reduced formalininduced and nerve injury-induced nociception by about 86 and 43%, respectively. (-)-Epicatechin-induced antinociception in the formalin test was prevented by the intraperitoneal administration of antagonists: Methiothepin (5-HT 1/5 receptor), WAY-100635 (5-HT 1A receptor), SB-224289 (5-HT 1B receptor), BRL-15572 (5-HT 1D receptor), SB-699551 (5-HT 5A receptor), naloxone (opioid receptor), CTAP (κopioid receptor), nor-binaltorphimine (δ 1 opioid receptor), and 7-benzylidenenaltrexone (δ 1 opioid receptor). The effect of (-)-epicatechin was also prevented by the intraperitoneal administration of L-NAME [nitric oxide (NO) synthase inhibitor], 7-nitroindazole (neuronal NO synthase inhibitor), ODQ (guanylyl cyclase inhibitor), glibenclamide (ATP-sensitive K + channel blocker), 4-aminopyridine (voltage-dependent K + channel blocker), and iberiotoxin (large-conductance Ca 2+ -activated K+ channel blocker), but not by amiloride (acid sensing ion channel blocker). The data suggest that (-)-epicatechin exerts its antinociceptive effects by activation of the NO-cyclic GMP-K+ channels pathway, 5-HT 1A/1B/1D/5A serotonergic receptors, and μ/κ/δ opioid receptors.
KW - (-)-epicatechin
KW - ASICs
KW - inflammation
KW - nitric oxide
KW - nociception
KW - opioids
KW - pain
KW - serotonin
UR - http://www.scopus.com/inward/record.url?scp=85020316727&partnerID=8YFLogxK
U2 - 10.1097/FBP.0000000000000320
DO - 10.1097/FBP.0000000000000320
M3 - Artículo
C2 - 28590304
SN - 0955-8810
VL - 29
SP - 270
EP - 279
JO - Behavioural Pharmacology
JF - Behavioural Pharmacology
ER -